Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Pulmatrix receives award from CF Foundation to support development of PUR1900 for lung infection in CF and asthma patients; shares up 30%

Published 09/05/2017, 03:37 PM
© Reuters.  Pulmatrix receives award from CF Foundation to support development of PUR1900 for lung infection in CF and asthma patients; shares up 30%
PULM
-
  • Pulmatrix (PULM +29.9%) announces the receipt of a financial award from the Cystic Fibrosis Foundation that will support the development of PUR1900 for the treatment of a lung infection called allergic bronchopulmonary aspergillosis that strikes people with cystic fibrosis (CF) and asthma. The award will help fund nonclinical safety studies needed for the Phase 1/1b clinical trial that will commence next year. The specific amount of the award is not disclosed.
  • PUR1900, with Orphan Drug and QIDP status in the U.S., incorporates the company's dry powder iSPERSE (inhaled small particles easily respirable and emitted) technology. The company says it overcomes the limitations of conventional lactose blend and metered dose inhaler technologies.


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.